# Vaccine Therapy in Treating Patients With Multiple Myeloma

> **NCT00019097** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Stage II Multiple Myeloma
- Stage III Multiple Myeloma
- Refractory Plasma Cell Neoplasm

## Interventions

- **DRUG:** autologous tumor cell vaccine
- **DRUG:** keyhole limpet hemocyanin
- **DRUG:** melphalan
- **DRUG:** sargramostim

## Key facts

- **NCT ID:** NCT00019097
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-07
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019097, "Vaccine Therapy in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00019097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*